|
|
Upfront Briefing
Monday actually has a pulse: argenx reopened the M&A window with its first takeout in a while, and Europe's regulators spent last week handing out rare-disease verdicts like a mixed report card. argenx is paying $2.2B in cash for Forte and its anti-CD122 antibody FB102, doubling down on immunology beyond the FcRn franchise. Over in Brussels, CHMP blessed Minoryx's leriglitazone in cerebral ALD but knocked back Zevra's Meplyffa — proof that an FDA approval buys you exactly nothing across the Atlantic.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,411.97 |
+0.1% |
+8.1% |
| Nasdaq 100 |
28,128.34 |
(1.2%) |
+11.6% |
| Russell 2000 |
2,930.00 |
(0.4%) |
+16.8% |
| Healthcare (XLV) |
162.57 |
+0.7% |
+4.5% |
| Biotech (XBI) |
150.48 |
(1.2%) |
+23.9% |
| Nasdaq Biotech (NBI) |
6,494.39 |
(0.5%) |
+13.8% |
| Clinical Trials (BBC) |
49.67 |
(1.3%) |
+32.0% |
|
- Healthcare split by market cap: large-cap pharma was one of the tape's few green corners, with XLV up 0.7%, while higher-beta biotech sold off alongside growth — XBI fell 1.2%, NBI 0.5% and BBC 1.3% — as the week's CHMP rare-disease verdicts and a run of pipeline setbacks kept small-cap sentiment defensive.
- Tech dragged the broad tape on a second straight semiconductor selloff — Intel fell nearly 8% despite a Q2 beat, pulling the Nasdaq 100 down 1.2% while the S&P 500 held roughly flat; new Section 301 tariffs (10–12.5%) took effect and oil eased on reported U.S.–Iran talks, leaving all three major indexes with weekly losses into Friday, 24 July 2026.
- Market data: U.S. cash close Friday, 24 July 2026.
The Big 3
|
1
|
argenx to buy Forte Biosciences for $2.2B
|
- argenx (ARGX) agreed to acquire Forte Biosciences (FBRX) for $77 per share in cash — roughly $2.2B, an ~86% premium to Forte’s VWAP since its 9 July vitiligo readout and ~41% over Friday’s close — turning a four-month-old strategic stake into a full takeover of FB102, a first-in-class anti-CD122 antibody. Funded from cash on hand; expected to close in Q3 2026.
- Why it matters: FB102 gives argenx a second mechanism to stand alongside FcRn: CD122, the shared beta subunit of the IL-2/IL-15 receptor, throttles pathogenic T-cell and NK-cell activity while sparing regulatory T cells. The Phase 1b vitiligo readout that triggered the deal was strong — 45.8% placebo-adjusted improvement — and the celiac program carries Fast Track plus a Phase 2 readout due H2 2026 that argenx will now own outright. At ~$2.2B for a Phase 1b asset, this is argenx paying up for early validation rather than de-risked data, betting the “pipeline-in-a-product” thesis across vitiligo, celiac and alopecia holds up. The class read is clean: anti-CD122/IL-15 autoimmune plays just printed a $2.2B comp.
- Source: FirstWord Pharma
- More: European Biotechnology; PR
|
| 2 | CHMP backs leriglitazone, rejects Zevra's Meplyffa |
-
NEZGLYAL, leriglitazone, won a positive CHMP opinion for cerebral Adrenoleukodystrophy, while Zevra's Meplyffa was rejected, setting up a sharply split rare-disease regulatory tape.
-
Why it matters:
The split outcome creates a clean divergence in the rare-disease tape: Minoryx moves closer to an EU launch and potential first meaningful commercial revenue in cALD, while Zevra now has to reassess ex-U.S. expansion assumptions for an already-approved U.S. asset. It is also a reminder that European regulators can diverge materially from FDA precedent, which matters for valuation models built on global rollout symmetry.
-
Source:
EMA
-
More:
PR; BioCentury
|
|
3
|
Roche axes acmopatide to focus its obesity bet on enicepatide
|
- Roche is discontinuing acmopatide (CT-868) — a Carmot-derived candidate that hit its primary A1C endpoint in a Phase 2 type 1 diabetes study — to concentrate its obesity effort on enicepatide (CT-388), the dual GLP-1/GIP agonist that posted up to 22.5% placebo-adjusted weight loss in Phase 2 and is now in Phase 3.
- Why it matters: Roche is concentrating fire: rather than fund three Carmot assets from its $2.7B buyout, it is backing the one molecule that can span obesity, T2D and cardiovascular outcomes. Enicepatide’s 22.5% ceiling lands just above Zepbound but below retatrutide, which is why Roche’s “best-in-class” tag has drawn analyst pushback — Jefferies flagged the ADA data as unlikely to shift the me-too read. Axing a Phase 2 winner to avoid portfolio sprawl is disciplined, but it concentrates the franchise’s fate on a single agent still trailing Lilly and Novo into a crowded Phase 3 field. Watch the mid-2026 enicepatide/petrelintide combo start for the real differentiation attempt.
- Source: BioSpace
- More: BioPharma Dive; Endpoints
|
Everything Else that broke
- FDA advisory committees return this week with Replimune and Capricor in focus. — BioSpace
- Big pharma interest boosts in vivo CAR-T, but safety still runs the model. — BioSpace
- A genetic analysis of Yescarta trial patients flagged inherited signatures that predict CAR-T toxicity risk, pointing toward safer next-gen designs. — Fierce Biotech
- CHMP backed Ubeslo and Evlarco, pushing obicetrapib closer to Europe. — PR
- Amgen cut around 40 employees as Tavneos and pipeline pressure build. — Fierce Biotech
- FDA's peptide panel rejected emideltide but backed two others, including epitalon. — STAT
- FDA approved OTC TYLENOL with Naproxen, a fixed-dose pain combo. — PR
- American Regent recalled one lot of papaverine injection over particulates. — PR
- Biogen's tau data stirred fresh debate across Alzheimer's investors and partners. — BioPharma Dive
- Summit faces FDA scrutiny of its China-first ivonescimab data with under a year of cash before the Nov. 14 PD-1/VEGF decision. — BioSpace
- Novo sought an injunction against Lilly's GLP-1 ads in obesity. — Fierce Pharma
- CHMP backed Roche's Susvimo for wet AMD in Europe. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
argenx agreed to acquire Forte Biosciences for FB102, a first-in-class anti-CD122 antibody. — PR
- Idorsia partnered with Jamjoom to commercialize QUVIVIQ in Saudi Arabia and the Levant. — PR
- Lilly's $3.8B AtaiBeckley psychedelics deal may validate the space without sparking copycats. — BioSpace
- Merck signed preapproval licenses for monthly HIV PrEP pill alimatravir. — Fierce Pharma
VC / Private Financings
- No new private financings since Friday's edition.
IPOs / Follow-Ons
- Scribe (SCTX) closed its Nasdaq debut up 44% at $21.65 after pricing an upsized $128.7M IPO at $15 — the first gene-editing IPO in over two years, and a firmer read on the issuance window. — BioPharma Dive
Academic Corner - Pulsatile liver in severe tricuspid regurgitation highlights a classic right-heart failure sign. — NEJM
|
That’s the tape — argenx cracks the M&A window back open, and Brussels reminds everyone the FDA’s homework doesn’t transfer.
— BioBucks Team
|
|
|
